← Back to Search

Intraocular Lens

Visual Results of the Acrysof IQ Vivity Toric Extended Vision Intraocular Lens

N/A
Waitlist Available
Led By Georges Durr, MD, FRCSC
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying a special lens used in cataract surgery that helps people see better at different distances and corrects astigmatism. These lenses have become the preferred choice for surgeons to correct vision issues during cataract surgery. The lens is designed to stay stable in the eye, which is important for clear vision. The goal is to reduce the need for glasses and improve quality of life for patients with significant astigmatism.

Eligible Conditions
  • Presbyopia
  • Pseudoaphakia
  • Cataract
  • Corneal Astigmatism

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Binocular uncorrected visual acuities for distance (6 meters), intermediate (66 centimeters), and near (40 centimeters)
Secondary study objectives
Mean absolute intraocular lens rotation (subjective)
Mean refractive spherical equivalent
Monocular best corrected distance visual acuities (at 6 meters), and distance corrected intermediate (66 centimeters) and near (40 centimeters) visual acuities
+4 more
Other study objectives
Mean absolute intraocular lens rotation (objective)
Mean absolute prediction error

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Acrysof IQ Vivity Toric Extended Vision Intraocular Lens ImplantationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation
2021
N/A
~20

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
377 Previous Clinical Trials
131,500 Total Patients Enrolled
Georges Durr, MD, FRCSCPrincipal InvestigatorCentre hospitalier de l'Université de Montréal (CHUM)
2 Previous Clinical Trials
140 Total Patients Enrolled
~4 spots leftby Dec 2025